Calyx
Calyx is recorded as a service provider in 13 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 13 of 13 trials · Latest update first
An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population with suspected or confirmed Gram negative infections, including but not restricted to Complicated Urinary Tract Infections.
Sponsor Menarini Ricerche S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-Label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients with Relapse / Refractory Metastatic or Advanced Solid Tumors
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available2 trial-level findings · Read insights
- The trial involved seven principal investigators across Spain and Poland.
- Following review of Part 1 preliminary efficacy data and the overall development program, the sponsor proceeded only with Part 2 Group E, including the food-effect substudy; the Part 2 efficacy-expansion groups were not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients with Moderate to Severe Ulcerative Colitis or Crohn’s Disease who completed the treatment phase of the Dose-Ranging Study (RELIEVE UCCD LTE)
Sponsor Teva Branded Pharmaceutical Products R&D LLC
- Start (EU)
- Latest update
- Estimated end
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemia
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II.
Sponsor Grin Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
Sponsor Aveo Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
Sponsor Astrazeneca AB
- Start (EU)
- Latest update
- Estimated end
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
Sponsor Teva Branded Pharmaceutical Products R&D Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP)
Sponsor Vigil Neuroscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Sponsor Ngm Biopharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Calyx?
The 2026-10-09 snapshot links Calyx to 13 distinct CTIS trials. Recorded services include Interactive response technology (IRT), Central imaging, Central Imaging, Electronic data capture, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Calyx?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology, Blood Disorders, Infectious Disease. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Calyx conducted?
The linked trials record locations in 23 countries, including Spain, Poland, Italy, France, Germany. These are trial locations, not confirmed office locations or countries where Calyx delivered services.
What can this page tell me about Calyx's trial experience?
Browse 13 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Calyx. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Calyx